ARROWHEAD PHARMACEUTICALS, INC. — Director's Dealing 2020

Apr 30, 2020

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: ARROWHEAD PHARMACEUTICALS, INC. (ARWR)
CIK: 0000879407
Period of Report: 2020-04-27

Reporting Person: GIVEN BRUCE D (Chief Operating Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2020-04-27	Common Stock	M	200	$5.19	Acquired	851934	Direct
2020-04-27	Common Stock	S	200	$40.00	Disposed	851734	Direct
2020-04-27	Common Stock	S	100	$40.00	Disposed	851634	Direct
2020-04-28	Common Stock	M	500	$7.75	Acquired	852134	Direct
2020-04-28	Common Stock	M	1454	$14.54	Acquired	853588	Direct
2020-04-28	Common Stock	M	1200	$4.75	Acquired	854788	Direct
2020-04-28	Common Stock	M	830	$5.19	Acquired	855618	Direct
2020-04-28	Common Stock	M	213	$5.20	Acquired	855831	Direct
2020-04-28	Common Stock	S	500	$40.00	Disposed	855331	Direct
2020-04-28	Common Stock	S	1454	$40.00	Disposed	853877	Direct
2020-04-28	Common Stock	S	1200	$40.00	Disposed	852677	Direct
2020-04-28	Common Stock	S	830	$40.00	Disposed	851847	Direct
2020-04-28	Common Stock	S	213	$40.00	Disposed	851634	Direct
2020-04-28	Common Stock	S	204	$40.00	Disposed	851430	Direct
2020-04-28	Common Stock	S	700	$40.00	Disposed	850730	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2020-04-27	Stock Option (right to buy)	$5.19	M	200	Disposed	2020-02-16	Common Stock (200)	Direct
2020-04-28	Stock Option (right to buy)	$7.75	M	500	Disposed	2025-03-06	Common Stock (500)	Direct
2020-04-28	Stock Option (right to buy)	$14.54	M	1454	Disposed	2024-02-06	Common Stock (1454)	Direct
2020-04-28	Stock Option (right to buy)	$4.75	M	1200	Disposed	2023-09-21	Common Stock (1200)	Direct
2020-04-28	Stock Option (right to buy)	$5.19	M	830	Disposed	2022-02-16	Common Stock (830)	Direct
2020-04-28	Stock Option (right to buy)	$5.20	M	213	Disposed	2021-10-26	Common Stock (213)	Direct

Footnotes

F1: Open market sale pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities
Exchange Act of 1934, as amended.

F2: The price reported on Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.00 to
$40.01, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead
Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares
sold at each separate price within the ranges set forth in this footnote of this Form 4.

F3: Represents first vesting date. Option vested over four years from date of grant.